MANE · XBRL financial data
Veradermics financial statements, every quarter
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (MANE's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | †Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Research and development | year only | 20,925 | 18,607 |
| General and administrative | year only | 8,937 | 10,946 |
| Total operating expenses | year only | 29,862 | 29,553 |
| Operating income (loss) | year only | (29,862) | (29,553) |
| Interest income | year only | 2,481 | 4,838 |
| Interest expense | year only | — | — |
| Income tax expense (benefit) | year only | 0 | 0 |
| Net income (loss) | year only | (27,232) | (23,502) |
| Earnings per share, basic USD per share | — | (1.32) | (0.58) |
| Earnings per share, diluted USD per share | — | (1.32) | (0.58) |
| Weighted average shares, basic thousands of shares | — | 22,704 | 40,436 |
| Weighted average shares, diluted thousands of shares | — | 22,704 | 40,436 |
- † Share count changed about 11x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (MANE's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | †Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 21,766 | 168,412 | 319,333 |
| Marketable securities | 120,096 | 222,385 | 500,561 |
| Prepaid and other current assets | 10,632 | 6,272 | 4,852 |
| Total current assets | 152,494 | 397,069 | 824,746 |
| Property and equipment, net | 22 | 21 | 41 |
| Right-of-use asset | 103 | 266 | 948 |
| Total assets | 152,619 | 397,356 | 825,735 |
| Accounts payable | 2,126 | 1,071 | 5,920 |
| Accrued liabilities | 6,979 | 5,606 | 5,395 |
| Total current liabilities | 9,152 | 6,716 | 11,694 |
| Lease liability, non-current | 4 | 0 | 428 |
| Total liabilities | 9,156 | 6,716 | 12,122 |
| Accumulated deficit | (123,421) | (150,653) | (174,155) |
| Total stockholders' equity | (121,014) | 390,640 | 813,613 |
| Total liabilities and equity | 152,619 | 397,356 | 825,735 |
| Common shares outstanding (cover page)‡ thousands of shares | 3,708 | 41,779 | 41,780 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-10.070493454179255 stock split (January 2026); filings made before it reported them unadjusted.
- † Share count changed about 11x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (MANE's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | †Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Net income (loss) | year only | (27,232) | (23,502) |
| Stock-based compensation | year only | 5,259 | 3,516* |
| Net cash from operating activities | year only | (21,168) | (14,490)* |
| Purchases of property and equipment | year only | 0 | 21* |
| Net cash from investing activities | year only | (101,299) | (277,287)* |
| Net cash from financing activities | year only | 269,113 | 442,698* |
| Net change in cash | year only | 146,646 | 150,921* |
- † Share count changed about 11x in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Veradermics | 319,333 | not reported | (14,490)* | 41.8M | 56.6 quarters | 10-QJun 30, 2026 |
| America Great Health | 29 | 26 | 1.7* | 21.2B | — | 10-QMar 31, 2026 |
| AbbVie | 10,774,000 | 17,404,000 | 7,606,000* | 1.8B | — | 10-QSep 30, 2026 |
| Abeona Therapeutics | 56,229 | 11,380 | (17,496)* | 57.2M | 8.4 quarters | 10-QJun 30, 2026 |
| Abbott Laboratories | 4,052,000 | 13,013,000 | 1,737,000* | 1.7B | — | 10-QSep 30, 2026 |
| Arbutus Biopharma | 19,171 | 1,014 | (6,018)* | 197.8M | 15.4 quarters | 10-QJun 30, 2026 |
| Abvc Biopharma | 32 | not reported | (244)* | 26.7M | 0.4 quarters | 10-QJun 30, 2026 |
| Acadia Pharmaceuticals | 322,365 | 342,291 | 11,503* | 172.8M | — | 10-QSep 30, 2026 |
| AC Immune | 26,795 | year only | year only | 101.7M | — | 20-FDec 31, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.